Search Within

Eytan Moshe Stein

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (201)
  2. Journal Article (99)
  3. Review (16)
  4. Research Letter (12)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (340)
  2. Center for Hematologic Malignancies (340)
  3. Department of Medicine (340)
  4. Hematologic Malignancies, Division of (340)
  5. GSK Faculty (84)
  6. Executive Committee, Center for Hematologic Malignancies (79)

More Groups

People
  1. Martin Tallman (114)
  2. Ross Levine (68)
  3. Aaron Goldberg (38)
  4. Jan Bewersdorf (31)
  5. Sean Devlin (28)
  6. Andriy Derkach (26)

More People

Years
  1. 2025 (6)
  2. 2024 (28)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (154)
  2. Journal of Clinical Oncology (22)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (13)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (168)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (25)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (14)
  6. Taylor & Francis Group (12)

More Publishers

Results (340)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2022)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2a/2b multicenter study of AG-946 in patients with anemia due to lower-risk myelodysplastic syndromes
    Meeting Abstract

    Al-Samkari, H.; Fenaux, P.; Sekeres, M. A.; Stein, E.; Sallman, D. A.; Brunner, A. M.; Gurov, X. D.; Yin, O.; Frisbie, M.; Xiao, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Nath, K.; Lee, J.; Elko, T. A.; Levy, L.; Preston, E.; Devlin, S. M.; Ponce, D. M.; Lin, R. J.; Shaffer, B. C.; Cho, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • MGTA-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): Safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1/2 study
    Meeting Abstract

    Westervelt, P.; Kebriaei, P.; Juckett, M.; Artz, A. S.; Chan, O.; McCarthy, P. L.; Farag, S. S.; Singh, A. K.; Stein, E.; Humphrey, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience
    Meeting Abstract

    Issa, G. C.; Cuglievan, B.; Stein, E.; Arellano, M. L.; Žucenka, A.; Khera, N.; Stone, R. M.; Thirman, M. J.; DiPersio, J. F.; Karras, N.; more...
    Blood (2022)

    Fulltext@MSK | Save